Jason Christopher Jones

Jason Christopher Jones

Auto-generated profile, based on publicly available information

Jason Christopher Jones

Department of Pharmacology University of Minnesota Minneapolis Minnesota USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 August 2020 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
VSVivek Srinivas
Vivek Srinivas
RBRahul Banerjee
Rahul Banerjee
HLHugo Lebrette
Hugo Lebrette
JJJason Christopher Jones
Jason Christopher Jones
OAOskar Aurelius
Oskar Aurelius
MHMartin Högbom
Martin Högbom


1 April 2021 in Journal of Hazardous Materials
Verified
Journal Article
Closed access
MFMark E. Fuller
Mark E. Fuller
RRRachael T. Rezes
Rachael T. Rezes
PHPaul C. Hedman
Paul C. Hedman
JJJason C. Jones
Jason C. Jones
NSNeil C. Sturchio
Neil C. Sturchio
PHPaul B. Hatzinger
Paul B. Hatzinger

8 June 2021 in Biochemistry
Verified
Journal Article
Closed access
JJJason C. Jones
Jason C. Jones
RBRahul Banerjee
Rahul Banerjee
KSKe Shi
Ke Shi
MSManny M. Semonis
Manny M. Semonis
HAHideki Aihara
Hideki Aihara
JLJohn D. Lipscomb
John D. Lipscomb

8 October 2025 in Journal of Extracellular Vesicles
Verified
Journal Article
Open access
MLMegan Ludwig
Megan Ludwig
AAAli T. Arafa
Ali T. Arafa
SVSaasha Vinoo
Saasha Vinoo
JJJason C. Jones
Jason C. Jones
ADAbderrahman Day
Abderrahman Day
JDJustin Drake
Justin Drake
Prostate cancer is the most common non‐cutaneous cancer among men in the United States. Most prostate cancers are driven by androgen receptor (AR) signalling, but there are an increasing number of cases that lose AR and gain neuroendocrine (NE) features (AR−/NE+) or lack both (AR−/NE−). These latter subtypes are particularly aggressive and lethal. Extracellular vesicles (EVs) have shown great potential as biomarkers for non‐invasive liquid biopsy assays, as EVs contain biomolecules from their cells of origin. Here, we used a shotgun proteomics approach with mass spectrometry to interrogate the global proteome of EVs isolated from prostate cancer cell lines reflecting diverse clinical subtypes, including AR−/NE+ and AR−/NE− models. We identified 3952 EV proteins, which clustered largely by tumour subtype and provided enough proteomic coverage to derive classic gene signatures of AR or NE identity that are of high relevance for prostate cancer prognostication. EVs isolated from AR+ cells displayed high levels of proteins regulated by AR and mTOR signalling. EVs isolated from AR−/NE+ cells contained known NE markers such as SYP and CHGA, whereas EVs from AR−/NE− models were enriched in basal cell markers and proteins that regulate epithelial‐to‐mesenchymal transition (EMT). We integrated our cell line data with recently published EV proteomics data from 27 advanced prostate cancer patients and found 2733 overlapping proteins, including cell surface markers relevant to prostate cancer, AR activity indicators, and proteins enriched in specific subtypes (AR+, AR−/NE−, AR−/NE+). This approach may be useful for rare cancer subtypes, such as prostate cancers that lose AR‐related features and gain NE features, to optimise the use of these liquid biopsy samples for clinical decision making.